

Chikashi Ishioka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3843286/publications.pdf>

Version: 2024-02-01

121
papers

4,743
citations

159358

30
h-index

102304

66
g-index

127
all docs

127
docs citations

127
times ranked

7466
citing authors

#	ARTICLE	IF	CITATIONS
1	A modified MethyLight assay predicts the clinical outcomes of anti-epidermal growth factor receptor treatment in metastatic colorectal cancer. <i>Cancer Science</i> , 2022, 113, 1057-1068.	1.7	7
2	Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial. <i>Anticancer Research</i> , 2022, 42, 2009-2015.	0.5	1
3	Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1259-1266.	0.9	6
4	Altered gene expression due to aberrant DNA methylation correlates with responsiveness to anti-EGFR antibody treatment. <i>Cancer Science</i> , 2022, , .	1.7	3
5	Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2022, 37, 1439-1447.	1.0	3
6	Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3131-3131.	0.8	1
7	Clinical impact of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3528-3528.	0.8	0
8	Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203). <i>Tohoku Journal of Experimental Medicine</i> , 2021, 254, 49-55.	0.5	1
9	LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11. <i>Cancer Science</i> , 2021, 112, 792-802.	1.7	2
10	Reply to comments on "Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei". <i>International Journal of Clinical Oncology</i> , 2021, 26, 621.	1.0	0
11	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer. <i>Cancer Science</i> , 2021, 112, 1567-1578.	1.7	5
12	Patients' understanding of communication about palliative care and health condition in Japanese patients with unresectable or recurrent cancer: a cross-sectional survey. <i>Annals of Palliative Medicine</i> , 2021, 10, 2650-2661.	0.5	4
13	lncRNA <i>HAR1B</i> has potential to be a predictive marker for pazopanib therapy in patients with sarcoma. <i>Oncology Letters</i> , 2021, 21, 455.	0.8	7
14	A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3141-TPS3141.	0.8	2
15	Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 393-402.	1.1	6
16	Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer. <i>Cancer Science</i> , 2021, 112, 3856-3870.	1.7	9
17	TP53 signature diagnostic system using multiplex reverse transcription-polymerase chain reaction system enables prediction of prognosis of breast cancer patients. <i>Breast Cancer</i> , 2021, 28, 1225-1234.	1.3	5
18	Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. <i>European Journal of Cancer</i> , 2021, 154, 296-306.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells. <i>Cancer Science</i> , 2021, 112, 4711-4721.	1.7	4
20	Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei. <i>International Journal of Clinical Oncology</i> , 2020, 25, 774-781.	1.0	15
21	A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial). <i>Medicine (United States)</i> , 2020, 99, e21457.	0.4	9
22	Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	0.6	13
23	Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 169-169.	0.8	4
24	Harmonization of Cardiovascular and Oncology and the Blossoming of Cardio-Oncology in Japan. <i>JACC: CardioOncology</i> , 2020, 2, 819-821.	1.7	2
25	In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells. <i>Cancer Medicine</i> , 2019, 8, 5662-5672.	1.3	9
26	Contribution of Fc γ 3 receptor IIB to creating a suppressive tumor microenvironment in a mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1769-1778.	2.0	5
27	<p>Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7953-7965.	0.9	19
28	Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 248, 37-43.	0.5	5
29	A Concise Approach for Producing Optically Pure Carboxylic Acid Segments for the Synthesis of Bicyclic Depsipeptide Histone Deacetylase Inhibitors. <i>Synthesis</i> , 2019, 51, 1408-1418.	1.2	4
30	A comparative analysis of clinicopathological factors between esophageal small cell and basaloid squamous cell carcinoma. <i>Medicine (United States)</i> , 2019, 98, e14363.	0.4	8
31	RACK1 regulates centriole duplication by controlling localization of BRCA1 to the centrosome in mammary tissue-derived cells. <i>Oncogene</i> , 2019, 38, 3077-3092.	2.6	25
32	Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome. <i>ELife</i> , 2019, 8, .	2.8	49
33	Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors. <i>International Journal of Clinical Oncology</i> , 2018, 23, 790-798.	1.0	11
34	Alcohol consumption and early-onset risk of colorectal cancer in Japanese patients with Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. <i>Surgery Today</i> , 2018, 48, 810-814.	0.7	16
35	Guidelines for treatment of renal injury during cancer chemotherapy 2016. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 210-244.	0.7	54
36	Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. <i>Oncotarget</i> , 2018, 9, 18698-18711.	0.8	127

#	ARTICLE	IF	CITATIONS
37	Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 3629-3636.	0.9	1
38	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq0 0,0,rgBT /Oyerglock 10	1.7	38
39	Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study. <i>Tohoku Journal of Experimental Medicine</i> , 2018, 245, 21-28.	0.5	5
40	Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis. <i>Tohoku Journal of Experimental Medicine</i> , 2018, 245, 123-129.	0.5	7
41	Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 913-919.	0.6	8
42	End-of-life care for cancer patients in Japanese acute care hospitals: A nationwide retrospective administrative database survey. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 877-883.	0.6	13
43	BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number. <i>Molecular Cancer Research</i> , 2018, 16, 1499-1511.	1.5	25
44	The consensus molecular subtypes of colorectal cancer as a predictive factor for chemotherapies against metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 736-736.	0.8	1
45	Molecular and clinical features of the <i>TP53</i> signature gene expression profile in early-stage breast cancer. <i>Oncotarget</i> , 2018, 9, 14193-14206.	0.8	11
46	Possible predictive value of G8 score and the drug concentrations for efficacy and toxicity of trifluridine/tipiracil for elderly patients with advanced colorectal cancer: A multicenter, phase II study (T-CORE1401).. <i>Journal of Clinical Oncology</i> , 2018, 36, e15516-e15516.	0.8	1
47	OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer. <i>Breast Cancer</i> , 2017, 24, 336-340.	1.3	4
48	IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity. <i>Cancer Immunology Research</i> , 2017, 5, 61-71.	1.6	36
49	Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines. <i>Oncology Reports</i> , 2017, 38, 31-42.	1.2	19
50	Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor. <i>Cancer Science</i> , 2017, 108, 1469-1475.	1.7	14
51	IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1485-1496.	2.0	57
52	Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. <i>PLoS ONE</i> , 2017, 12, e0176972.	1.1	13
53	The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study. <i>PLoS ONE</i> , 2017, 12, e0179694.	1.1	75
54	microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. <i>BMC Cancer</i> , 2017, 17, 723.	1.1	28

#	ARTICLE	IF	CITATIONS
55	Current situation regarding central venous port implantation procedures and complications: a questionnaire-based survey of 11,693 implantations in Japan. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1172-1182.	1.0	22
56	Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma. <i>Chemotherapy</i> , 2016, 61, 262-268.	0.8	10
57	CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1091-1101.	1.0	20
58	Enantioselective Total Synthesis of (â€“)â€“Siphonodictyal B and (+)â€“8â€“ <i>epi</i> â€“Siphonodictyal B with Phosphatidylinositol 3â€“Kinase Î± (PI3KÎ±) Inhibitory Activity. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 5659-5666.	1.2	8
59	Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs. <i>International Cancer Conference Journal</i> , 2016, 5, 163-167.	0.2	1
60	A Preliminary Survey to Measure the Quality Indicators of End-of-life Cancer Care Using the Japanese National Database. <i>Palliative Care Research</i> , 2016, 11, 156-165.	0.0	3
61	Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome. <i>Anticancer Research</i> , 2016, 36, 1985-9.	0.5	6
62	Functional Complementation Assay for 47 <i>MUTYH</i> Variants in a <i>MutY</i> â€“Disrupted <i>Escherichia Coli</i> Strain. <i>Human Mutation</i> , 2015, 36, 704-711.	1.1	23
63	Somatic alteration and depleted nuclear expression of BAP 1 in human esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2015, 106, 1118-1129.	1.7	20
64	DNA methylation status as a biomarker of antiâ€“epidermal growth factor receptor treatment for metastatic colorectal cancer. <i>Cancer Science</i> , 2015, 106, 1722-1729.	1.7	25
65	Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells. <i>Scientific Reports</i> , 2015, 5, 13249.	1.6	57
66	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 626.	1.1	13
67	Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1026-1034.	2.1	30
68	Biochemical, biological and structural properties of romidepsin (<sc>FK</sc>228) and its analogs as novel <sc>HDAC</sc>/<sc>PI</sc>3K dual inhibitors. <i>Cancer Science</i> , 2015, 106, 208-215.	1.7	35
69	Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality. <i>Scientific Reports</i> , 2015, 4, 5927.	1.6	2
70	Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1147-1155.	1.0	11
71	Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients with colorectal cancer: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 153-159.	0.6	28
72	Inhibition of invasion by glycogen synthase kinase-3 beta inhibitors through dysregulation of actin re-organisation via down-regulation of WAVE2. <i>Biochemical and Biophysical Research Communications</i> , 2015, 464, 275-280.	1.0	7

#	ARTICLE	IF	CITATIONS
73	Relationship between smoking and multiple colorectal cancers in patients with Japanese Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 307-310.	0.6	9
74	Analysis of administrative data to investigate end-of-life cancer care in a Japanese university hospital: development of methodology. <i>Palliative Care Research</i> , 2015, 10, 177-185.	0.0	2
75	KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. <i>Molecular and Clinical Oncology</i> , 2014, 2, 356-362.	0.4	5
76	Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801). <i>Oncology</i> , 2014, 87, 7-20.	0.9	69
77	The BRCA1/BARD1-Interacting Protein OLA1 Functions in Centrosome Regulation. <i>Molecular Cell</i> , 2014, 53, 101-114.	4.5	60
78	Predicting the structures of complexes between phosphoinositide 3-kinase (PI3K) and romidepsin-related compounds for the drug design of PI3K/histone deacetylase dual inhibitors using computational docking and the ligand-based drug design approach. <i>Journal of Molecular Graphics and Modelling</i> , 2014, 54, 46-53.	1.3	13
79	High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H. <i>Oncology Reports</i> , 2014, 31, 1043-1050.	1.2	7
80	Upper Arm Central Venous Port Implantation: A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion. <i>PLoS ONE</i> , 2014, 9, e91335.	1.1	31
81	Acute exacerbation of paraneoplastic neurological syndrome after massive tumor lysis of neuroendocrine carcinoma by chemoradiotherapy. <i>International Cancer Conference Journal</i> , 2013, 2, 247-250.	0.2	4
82	Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2013, 18, 670-677.	1.0	32
83	Overexpression of DRAM enhances p53-dependent apoptosis. <i>Cancer Medicine</i> , 2013, 2, 1-10.	1.3	23
84	Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients. <i>Oncology</i> , 2012, 83, 101-107.	0.9	9
85	Aberrant splicing caused by a MLH1 splice donor site mutation found in a young Japanese patient with Lynch syndrome. <i>Familial Cancer</i> , 2012, 11, 559-564.	0.9	6
86	Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors. <i>Cancer Science</i> , 2012, 103, 1994-2001.	1.7	43
87	Multidisciplinary approach to a case of Lynch syndrome with colorectal, ovarian, and metastatic liver carcinomas. <i>International Cancer Conference Journal</i> , 2012, 1, 125-137.	0.2	0
88	Three cases of kindred with familial breast cancer in which carrier detection by BRCA gene testing was performed on family members. <i>Breast Cancer</i> , 2012, 19, 270-274.	1.3	1
89	Contribution of autophagic cell death to p53-dependent cell death in human glioblastoma cell line SF126. <i>Cancer Science</i> , 2011, 102, 799-807.	1.7	14
90	Identification of Breast Tumor Mutations in BRCA1 That Abolish Its Function in Homologous DNA Recombination. <i>Cancer Research</i> , 2010, 70, 988-995.	0.4	116

#	ARTICLE	IF	CITATIONS
91	Determination of splice-site mutations in Lynch syndrome (hereditary non-polyposis colorectal) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	13
92	Î±Bâ€crystallin: A novel p53â€target gene required for p53â€dependent apoptosis. Cancer Science, 2009, 100, 2368-2375.	1.7	52
93	Prediction of breast cancer prognosis by gene expression profile of <i>TP53</i> status. Cancer Science, 2008, 99, 324-332.	1.7	31
94	Functional Analysis of Human MLH1 Variants Using Yeast and In vitro Mismatch Repair Assays. Cancer Research, 2007, 67, 4595-4604.	0.4	128
95	The screening of the second-site suppressor mutations of the common p53 mutants. International Journal of Cancer, 2007, 121, 559-566.	2.3	24
96	The Role of Chemotherapy in Brain Metastases(<SPECIAL ISSUE> Current Management of Brain) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	0.0	2
97	4. Role of Chemotharapy on Metastatic Brain Tumor(PS1-4 Modern Management of Metastatic Brain) Tj ETQq1 1 0.784314 rgBT /Overlock 0	0.0	0
98	The UMD TP53 database and website: update and revisions. Human Mutation, 2006, 27, 14-20.	1.1	125
99	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.. Clinical Cancer Research, 2006, 12, 1157-1167.	3.2	495
100	Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection. Clinical Cancer Research, 2006, 12, 62-69.	3.2	67
101	The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene, 2005, 24, 6976-6981.	2.6	89
102	BRCA1/BARD1 Ubiquitinate Phosphorylated RNA Polymerase II. Journal of Biological Chemistry, 2005, 280, 24498-24505.	1.6	126
103	Lack of Correlation between p53-Dependent Transcriptional Activity and the Ability to Induce Apoptosis among 179 Mutant p53s. Cancer Research, 2005, 65, 2108-2114.	0.4	83
104	Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library. Journal of Biological Chemistry, 2004, 279, 348-355.	1.6	78
105	Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families. Journal of Human Genetics, 2004, 49, 391-395.	1.1	13
106	Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1 and BRCA2 genes in familial breast cancer. Journal of Human Genetics, 2003, 48, 0130-0137.	1.1	12
107	Analysis of the humanAPC mutation spectrum in asaccharomyces cerevisiae strain with a mismatch repair defect. International Journal of Cancer, 2003, 103, 624-630.	2.3	4
108	Understanding the functionâ€structure and functionâ€mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8424-8429.	3.3	710

#	ARTICLE	IF	CITATIONS
109	Mutational analysis of p51A/TAp63 ^{Δ3} , a p53 homolog, in non-small cell lung cancer and breast cancer. <i>Oncogene</i> , 1999, 18, 3761-3765.	2.6	54
110	BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening. <i>Breast Cancer Research and Treatment</i> , 1999, 58, 11-17.	1.1	10
111	A New Combination Chemotherapy with Cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for Advanced Esophageal Cancers.. <i>Internal Medicine</i> , 1999, 38, 844-848.	0.3	25
112	Functional analysis of human MLH1 mutations in <i>Saccharomyces cerevisiae</i> . <i>Nature Genetics</i> , 1998, 19, 384-389.	9.4	136
113	Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. <i>Oncogene</i> , 1998, 17, 727-731.	2.6	57
114	Cloning and functional analysis of human p51, which structurally and functionally resembles p53. <i>Nature Medicine</i> , 1998, 4, 839-843.	15.2	497
115	Detection of APC mutations by a yeast-based protein truncation test (YPTT). , 1998, 21, 290-297.		7
116	Detection of APC mutations by a yeast-based protein truncation test (YPTT). <i>Genes Chromosomes and Cancer</i> , 1998, 21, 290-297.	1.5	1
117	Oligomerization Is Not Essential for Growth Suppression by p53 in p53-Deficient Osteosarcoma Saos-2 Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 232, 54-60.	1.0	18
118	Induction of p53-independent Apoptosis Associated with G2M Arrest Following DNA Damage in Human Colon Cancer Cell Lines. <i>Japanese Journal of Cancer Research</i> , 1997, 88, 39-43.	1.7	37
119	Mutation in p53 and de-regulation of p53-related gene expression in three human cell lines immortalized with 4-nitroquinoline 1-oxide or ⁶⁰ Co gamma rays. , 1996, 66, 698-702.		15
120	Screening patients for heterozygous p53 mutations using a functional assay in yeast. <i>Nature Genetics</i> , 1993, 5, 124-129.	9.4	243
121	Expression of glutathione S-transferase- α messenger rna in human esophageal cancers. <i>Cancer</i> , 1991, 67, 2560-2564.	2.0	22